Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9504704 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US9078870 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US10624918 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US10137142 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US9561208 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US8663699 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US8895070 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(5 years from now) |
Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 23 October, 2008
Treatment: Treatment of acne vulgaris; Topical treatment of acne vulgaris; Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(6 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7696159 (Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(1 year, 3 days from now) |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) | |
US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) |
Drugs and Companies using BUPROPION HYDROBROMIDE ingredient
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11679116 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US11311482 | BAUSCH | Topical compositions and methods for treating skin diseases |
May, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Dec 18, 2022 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2018
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
US10251895 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US11679115 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US11648256 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
US10426787 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Apr 25, 2022 |
Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient
Market Authorisation Date: 25 April, 2019
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(2 years from now) | |
US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(4 years from now) | |
US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(7 years from now) | |
US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(7 years from now) | |
US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(11 years from now) | |
US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(11 years from now) | |
US11654139 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(11 years from now) | |
US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(11 years from now) | |
US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(11 years from now) | |
US10478601 | BAUSCH | Applicator |
Apr, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of the toe...
Dosage: SOLUTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7981877 | BAUSCH | Stabilized steroid composition and method for its preparation |
Jan, 2025
(1 year, 3 months from now) | |
US7378405 | BAUSCH | Stabilized steroid composition and method for its preparation |
Dec, 2026
(3 years from now) |
Drugs and Companies using HYDROCORTISONE BUTYRATE ingredient
Market Authorisation Date: 18 May, 2007
Treatment: NA
Dosage: LOTION;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(9 years from now) | |
US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(9 years from now) | |
US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(10 years from now) |
Drugs and Companies using LULICONAZOLE ingredient
Market Authorisation Date: 14 November, 2013
Treatment: Treatment of fungal infections
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8268804 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 8 months from now) | |
US7790705 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 8 months from now) | |
US8722650 | BAUSCH | Extended-release minocycline dosage forms |
Jun, 2025
(1 year, 8 months from now) | |
US8252776 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 8 months from now) | |
US7919483 | BAUSCH | Method for the treatment of acne |
Mar, 2027
(3 years from now) | |
US7544373 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(3 years from now) | |
US7541347 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(3 years from now) | |
US9192615 | BAUSCH | Method for the treatment of acne and certain dosage forms thereof |
Nov, 2031
(8 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2006
Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7794738 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Sep, 2022
(1 year, 17 days ago) | |
US7220424 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Jan, 2023
(8 months ago) | |
US8232264 | BAUSCH | Compositions and methods for enhancing corticosteroid delivery |
Mar, 2023
(6 months ago) |
Drugs and Companies using FLUOCINONIDE ingredient
Market Authorisation Date: 11 February, 2005
Treatment: Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7223387 | BAUSCH | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
Nov, 2022
(10 months ago) |
Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolesc...
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8598196 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Aug, 2029
(5 years from now) | |
US10238645 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Aug, 2029
(5 years from now) | |
US10238644 | BAUSCH | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(6 years from now) | |
US11318130 | BAUSCH | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(6 years from now) | |
US8299109 | BAUSCH | Method of treating actinic keratosis with 3.75% imiquimod cream |
Dec, 2029
(6 years from now) | |
US8222270 | BAUSCH | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
Dec, 2029
(6 years from now) | |
US8236816 | BAUSCH | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
Dec, 2029
(6 years from now) | |
US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(6 years from now) | |
US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(6 years from now) |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 25 March, 2010
Treatment: Treatment of genital warts; Treatment of perianal warts; Treatment of actinic keratosis
Dosage: CREAM;TOPICAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic